Skip to main content

Table 4 Adverse events

From: Combination chemoradiotherapy with temozolomide, vincristine, and interferon-β might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma

 

Grade 1 (%)

Grade 2 (%)

Grade 3 (%)

Grade 4 (%)

Grade 3 + 4%

Hematological

 Anemia

14 (29.8)

19 (40.4)

0

0

0.0

 Neutropenia

6 (12.8)

18 (38.3)

8 (17.0)

1 (2.1)

19.1

 Lymphopenia

3 (6.4)

3 (6.4)

28 (59.6)

13 (27.7)

87.3

 Thrombopenia

21 (44.7)

9 (19.2)

2 (4.3)

2 (4.3)

8.6

Non-hematological

 Nausea

7 (14.9)

5 (10.6)

2 (4.3)

0

4.3

 Vomiting

4 (8.5)

4 (8.5)

1 (2.1)

0

2.1

 Anorexia

16 (34.0)

7 (14.9)

4 (8.5)

0

8.5

 Constipation

12 (25.5)

26 (55.3)

0

0

0.0

 ALT elevation

16 (34.0)

10 (21.3)

2 (4.3)

0

4.3

 Hyponatremia

26 (55.3)

3 (6.4)

2 (4.3)

0

4.3

 Hyperpotassemia

11 (23.4)

1 (2.1)

1 (2.1)

0

2.1

 Skin rush

3 (6.4)

4 (8.5)

0

0

0.0

 Fever

15 (31.9)

0

0

0

0.0

 Febrile neutropenia

0

0

0.0

Others

3 (6.4)

0

3 (6.4)

0

6.4

  1. Others: Interferon-associated retinopathy (G3) 1 case, hydrocephalus(G3) 2 cases, and Peripheral sensory neuropathy(G1) 3 cases